Deutsch English Français

Contact

EP1364968

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1364968

EP1364968 - Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 1 (AVPR1) [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 03.11.2006 Database last updated on 11.09.2024
Most recent event Tooltip	03.11.2006	Application deemed to be withdrawn	published on 06.12.2006 [2006/49]
Applicant(s)	For all designated states Bayer HealthCare AG 51368 Leverkusen / DE
	[2004/01]
Former [2003/48]	For all designated states Bayer Aktiengesellschaft 51368 Leverkusen / DE
Inventor(s)	01 / Golz, Stefan, Dr. Bückmannmühle 46 45329 Essen / DE
	02 / Brüggemeier, Ulf, Dr. Leysiefen 20 42799 Leichlingen / DE
	03 / Geerts, Andreas Schuckertstrasse 29 42113 Wuppertal / DE
	04 / Thiele, Ralf, Dr. Ebbinghauser Strasse 13 33178 Borchen / DE
	[2003/48]
Application number, filing date	02011530.9	23.05.2002
	[2003/48]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP1364968
	Date:	26.11.2003
	Language:	EN
	[2003/48]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	07.11.2002
Classification	IPC:	C07K14/72	[2003/48]
	CPC:	C07K14/705 (EP)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/48]
Title	German:	Diagnostika und Therapeutika für Krankheiten, die mit Arginin-Vasopressin-Rezeptor 1 (AVPR1) assoziiert sind	[2003/48]
	English:	Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 1 (AVPR1)	[2003/48]
	French:	Diagnostic et traitement des maladies associées au récepteur 1 d'arginine-vasopressine (AVPR1)	[2003/48]
Examination procedure	26.05.2004	Examination requested [2004/31]
	08.02.2006	Despatch of a communication from the examining division (Time limit: M04)
	20.06.2006	Application deemed to be withdrawn, date of legal effect [2006/49]
	21.07.2006	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2006/49]
Fees paid	Renewal fee
	01.06.2004	Renewal fee patent year 03
	31.05.2005	Renewal fee patent year 04
	31.05.2006	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]JPH0880193 ;
		[X]WO0043398 (ORTHO MCNEIL PHARM INC [US]) [X] 1,4-6,8-10,19-21,24-26 * abstract, Example 50, claims 1 - 18 *;
		[X]WO0177172 (ARENA PHARM INC [US], et al) [X] 1-6,8-10 * p. 1, lines 8 - 13, p. 12, table B, p. 19, line 4 - p. 22, line 4, p. 33, lin1 - p. 34, line 3, p. 66, Seq Id Nos. 452 & 453, Examples 3, 4, , claims 1 and 16 *;
		[X]WO0202531 (ORTHO MCNEIL PHARM INC [US]) [X] 1-6,8-10,19-21,24-26 * abstract, example 49, tables I - V *;
		[X] - PATENT ABSTRACTS OF JAPAN, (19960731), vol. 1996, no. 07, & JP08080193 A 19960326 (OTSUKA PHARMACEUT CO LTD) [X] 1-26 * abstract * * Sequences p. 7 - p. 10 *
		[X] - YAMAMURA Y ET AL, "OPC-21268 AN ORALLY EFFECTIVE NONPEPTIDE VASOPRESSIN V1 RECEPTOR ANTAGONIST", SCIENCE (WASHINGTON D C), (1991), vol. 252, no. 5005, ISSN 0036-8075, pages 572 - 574, XP001118282 [X] 1,3,5,6,8-10,19-21,24-26 * the whole document * DOI: http://dx.doi.org/10.1126/science.1850553
		[X] - HOWL JOHN ET AL, "Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by L-amino acids.", BIOCHEMICAL PHARMACOLOGY, (1994), vol. 47, no. 9, ISSN 0006-2952, pages 1497 - 1501, XP001107126 [X] 1-10,19-21,24-26 * the whole document * DOI: http://dx.doi.org/10.1016/0006-2952(94)90523-1
		[A] - THIBONNNIER M ET AL, "STRUCTURE, SEQUENCE, EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF THE HUMAN V1A VASOPRESSIN RECEPTOR GENE", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, (1996), vol. 31, no. 3, ISSN 0888-7543, pages 327 - 334, XP000979403 [A] 1-26 * the whole document * DOI: http://dx.doi.org/10.1006/geno.1996.0055
		[A] - ARNALDI GIORGIO ET AL, "Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, (199806), vol. 83, no. 6, ISSN 0021-972X, pages 2029 - 2035, XP001118067 [A] 1-26 * abstract, p. 2030, col. 1, line 51 - p. 2031, col. 1, line 42, * DOI: http://dx.doi.org/10.1210/jc.83.6.2029

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p